Methylmercury toxic mechanism related to protein degradation and chemokine transcription.


Journal

Environmental health and preventive medicine
ISSN: 1347-4715
Titre abrégé: Environ Health Prev Med
Pays: Japan
ID NLM: 9609642

Informations de publication

Date de publication:
17 Jul 2020
Historique:
received: 02 04 2020
accepted: 29 06 2020
entrez: 19 7 2020
pubmed: 19 7 2020
medline: 20 9 2020
Statut: epublish

Résumé

Methylmercury is an environmental pollutant that causes neurotoxicity. Recent studies have reported that the ubiquitin-proteasome system is involved in defense against methylmercury toxicity through the degradation of proteins synthesizing the pyruvate. Mitochondrial accumulation of pyruvate can enhance methylmercury toxicity. In addition, methylmercury exposure induces several immune-related chemokines, specifically in the brain, and may cause neurotoxicity. This summary highlights several molecular mechanisms of methylmercury-induced neurotoxicity.

Identifiants

pubmed: 32680455
doi: 10.1186/s12199-020-00868-3
pii: 10.1186/s12199-020-00868-3
pmc: PMC7469908
doi:

Substances chimiques

Chemokines 0
Methylmercury Compounds 0
Neurotoxins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

30

Références

FEBS Lett. 2015 Sep 14;589(19 Pt B):2720-5
pubmed: 26297823
J Biol Chem. 1982 Jun 25;257(12):7181-8
pubmed: 6282834
Brain Res. 1996 Nov 4;738(2):257-64
pubmed: 8955521
J Neurosci. 2006 Oct 25;26(43):11083-110
pubmed: 17065450
Braz J Med Biol Res. 2007 Mar;40(3):285-91
pubmed: 17334523
Cell. 1997 Oct 17;91(2):209-19
pubmed: 9346238
Sci Rep. 2019 Mar 15;9(1):4631
pubmed: 30874621
J Toxicol Sci. 2018;43(2):89-100
pubmed: 29479038
Environ Res. 2013 Aug;125:131-49
pubmed: 23489986
Life Sci. 2012 Apr 9;90(13-14):525-30
pubmed: 22326498
Prog Mol Biol Transl Sci. 2019;168:351-379
pubmed: 31699326
Environ Health Perspect. 2002 Feb;110 Suppl 1:11-23
pubmed: 11834460
Science. 1988 Sep 9;241(4871):1331-5
pubmed: 2842867
Crit Rev Toxicol. 1995;25(1):1-24
pubmed: 7734058
Sci Rep. 2017 Dec 11;7(1):17287
pubmed: 29229987
J Neurosci. 2008 Nov 12;28(46):11980-8
pubmed: 19005063
Neurotoxicology. 1995 Winter;16(4):705-10
pubmed: 8714874
Crit Rev Clin Lab Sci. 1997;34(4):369-403
pubmed: 9288445
J Toxicol Sci. 2012;37(6):1279-82
pubmed: 23208444
J Toxicol Sci. 2013;38(6):925-9
pubmed: 24213012
Sci Rep. 2016 Feb 22;6:21528
pubmed: 26899208
Curr Opin Microbiol. 2003 Apr;6(2):198-201
pubmed: 12732312
N Engl J Med. 2003 Oct 30;349(18):1731-7
pubmed: 14585942
Toxicol Ind Health. 2002 Apr;18(3):109-60
pubmed: 12974562
PLoS One. 2018 Jul 16;13(7):e0197220
pubmed: 30011281
Mol Pharmacol. 2002 Apr;61(4):738-41
pubmed: 11901211
Trends Neurosci. 2013 Oct;36(10):587-97
pubmed: 23968694
FEBS Lett. 2006 Dec 22;580(30):6813-8
pubmed: 17141224
Crit Rev Toxicol. 2006 Sep;36(8):609-62
pubmed: 16973445
Nat Rev Neurosci. 2007 Nov;8(11):895-903
pubmed: 17948033
J Toxicol Sci. 2012;37(6):1275-8
pubmed: 23208443
FASEB J. 2002 May;16(7):709-11
pubmed: 11978736
J Toxicol Sci. 2011 Jun;36(3):389-91
pubmed: 21628967
Yeast. 1999 Sep 30;15(13):1377-91
pubmed: 10509019
Tohoku J Exp Med. 2007 Nov;213(3):187-202
pubmed: 17984616

Auteurs

Jin-Yong Lee (JY)

Laboratory of Pharmaceutical Health Sciences, School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, 464-8650, Japan. leejy@dpc.agu.ac.jp.

Gi-Wook Hwang (GW)

Laboratory of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, 981-8558, Japan.
Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.

Akira Naganuma (A)

Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.

Masahiko Satoh (M)

Laboratory of Pharmaceutical Health Sciences, School of Pharmacy, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya, 464-8650, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH